Clinical Trials for Carcinoid syndrome
Clinical trials are research studies conducted in an effort to improve overall patient health and care.
Each trial involves running supervised tests to determine the effectiveness and safety of new drugs, procedures and/or devices with the aim of answering scientific questions about a disease or condition.
Risks and side-effects are also evaluated during these trials with results ranging from being unpleasant, with side effects such as headaches, to more serious or even life-threatening risks.
A clinical trial may be separated into phases, or steps, with each step designed to answer a separate research question. This maybe reflected in the trial name.
A brief description of each phase:
- Phase I: Usually designed to evaluate safety, determine a safe dosage range, and identify side effects on a small group of patients.
- Phase II: If Phase I is successful, the trial is then repeated with a larger group to further evaluate its effect and safety.
- Phase III: Trials are conducted on an ever larger group and are compared with the best current treatment while gathering more information on effect and safety.
- Phase IV: These studies monitor long-term side effects after the treatment has been marketed.
Clinical Trials data for Carcinoid syndrome is grouped into the following categories:-
The format for each of the following is:
- The name of the trial,
- followed by whether the trial is recruiting patients,
- The trial may not have started and not yet recruiting, or the trial may have started and do not need any more recruitements, or the trial may be completed.
- Note**: Please follow the link to determine the current trial status.
- followed by a list of drug/s, if any, used in the trial
ClinicalTrials.gov has listed the following trials for Carcinoid syndrome:
- Comparison of Lanreotide Autogel and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome - This study has been terminated (Current: 23 Nov 2006) - lanreotide Autogel (somatostatin analogue),Sandostatin long acting release (LAR) Depot (somatostatin analogue)
- Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors - This study has been completed (Current: 23 Nov 2006) - fluorouracil,interferon alfa
- PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors - This study has been completed (Current: 23 Nov 2006) - PS-341
- Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors - This study is no longer recruiting patients (Current: 23 Nov 2006) - thalidomide
- Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors - This study is currently recruiting patients (Current: 23 Nov 2006) - yttrium Y 90-DOTA-tyr3-octreotide
- Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors - This study is no longer recruiting patients (Current: 23 Nov 2006) - PEG-interferon alfa-2b,bevacizumab
- BB-10901 in Treating Patients With Recurrent or Refractory Lung Cancer, Metastatic Carcinoid Tumor, or Other Solid Tumors - This study is currently recruiting patients (Current: 23 Nov 2006) - BB-10901
- Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors - This study has been suspended (Current: 23 Nov 2006) - gefitinib
- FR901228 in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors - This study is no longer recruiting patients (Current: 23 Nov 2006) - FR901228
- CCI-779 in Treating Patients With Progressive Metastatic Neuroendocrine Tumors - This study is no longer recruiting patients (Current: 23 Nov 2006) - temsirolimus
- Sorafenib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors - This study is currently recruiting patients (Current: 23 Nov 2006) - sorafenib
- Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors - This study is currently recruiting patients (Current: 23 Nov 2006) - bevacizumab,fluorouracil,leucovorin calcium,oxaliplatin
- Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors - This study is not yet open for patient recruitment (Current: 23 Nov 2006) - octreotide acetate,vatalanib
- BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors - This study is currently recruiting patients (Current: 23 Nov 2006) - BB-10901
- Safety and Efficacy Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone - This study is currently recruiting patients (Current: 23 Nov 2006) - Denosumab
- Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors - This study is no longer recruiting patients (Current: 23 Nov 2006) - Sandostatin LAR,SOM230
The format for each of the following is:
- The drug,
- followed by the name of the trial,
- followed by whether the trial is recruiting patients,
- The trial may not have started and not yet recruiting, or the trial may have started and do not need any more recruitements, or the trial may be completed.
- Note**: Please follow the link to determine the current trial status.
ClinicalTrials.gov has listed the following drugs in trials for Carcinoid syndrome:
The trial data on this page has been sourced from
